Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide

J. B. Chalk, M. Patterson, M. T. Smith, M. J. Eadie

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

A study has been carried out investigating four different marketed oral preparations of glibenclamide, correlating the effectiveness of the drug in these preparations in lowering plasma glucose concentrations with (i) the in vitro dissolution of the drug, measured by the British Pharmacopoeal and Desaga methods, and (ii) the in vivo bioavailability, assessed in 12 healthy human volunteers. The two dissolution methods yielded different rank orders of ease of dissolution of the drug from the various preparations; the findings of neither dissolution method correlated adequately with the results of the in vivo bioavailability studies, which correctly predicted the abilities of the preparations to reduce plasma glucose concentrations. Relative to an oral glibenclamide solution the bioavailabilities of the drug from three tablet preparations were 0.69, 0.49 and 0.24. The mean elimination half-life of the drug was 1.5 h and assuming complete bioavailability of the drug from oral solution the mean systemic clearance was 0.095 l kg-1h-1, and the mean apparent volume of distribution was 0.20 l kg-1. It is concluded that it may be unsafe to use in vitro dissolution data as a basis for assessing the bioequivalences of different glibenclamide preparations intended for oral use.

Original languageEnglish (US)
Pages (from-to)177-182
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume31
Issue number2
DOIs
StatePublished - Mar 1986
Externally publishedYes

Fingerprint

Glyburide
Hypoglycemic Agents
Biological Availability
Drug Compounding
Pharmaceutical Preparations
Glucose
Therapeutic Equivalency
Tablets
Half-Life
Healthy Volunteers
In Vitro Techniques

Keywords

  • bioavailability
  • dissolution
  • glibenclamide
  • healthy volunteers
  • hypoglycaemia
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. / Chalk, J. B.; Patterson, M.; Smith, M. T.; Eadie, M. J.

In: European Journal of Clinical Pharmacology, Vol. 31, No. 2, 03.1986, p. 177-182.

Research output: Contribution to journalArticle

Chalk, J. B. ; Patterson, M. ; Smith, M. T. ; Eadie, M. J. / Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. In: European Journal of Clinical Pharmacology. 1986 ; Vol. 31, No. 2. pp. 177-182.
@article{6ccb94c172a14a9c8efaedbc06b9e5fc,
title = "Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide",
abstract = "A study has been carried out investigating four different marketed oral preparations of glibenclamide, correlating the effectiveness of the drug in these preparations in lowering plasma glucose concentrations with (i) the in vitro dissolution of the drug, measured by the British Pharmacopoeal and Desaga methods, and (ii) the in vivo bioavailability, assessed in 12 healthy human volunteers. The two dissolution methods yielded different rank orders of ease of dissolution of the drug from the various preparations; the findings of neither dissolution method correlated adequately with the results of the in vivo bioavailability studies, which correctly predicted the abilities of the preparations to reduce plasma glucose concentrations. Relative to an oral glibenclamide solution the bioavailabilities of the drug from three tablet preparations were 0.69, 0.49 and 0.24. The mean elimination half-life of the drug was 1.5 h and assuming complete bioavailability of the drug from oral solution the mean systemic clearance was 0.095 l kg-1h-1, and the mean apparent volume of distribution was 0.20 l kg-1. It is concluded that it may be unsafe to use in vitro dissolution data as a basis for assessing the bioequivalences of different glibenclamide preparations intended for oral use.",
keywords = "bioavailability, dissolution, glibenclamide, healthy volunteers, hypoglycaemia, pharmacokinetics",
author = "Chalk, {J. B.} and M. Patterson and Smith, {M. T.} and Eadie, {M. J.}",
year = "1986",
month = "3",
doi = "10.1007/BF00606655",
language = "English (US)",
volume = "31",
pages = "177--182",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide

AU - Chalk, J. B.

AU - Patterson, M.

AU - Smith, M. T.

AU - Eadie, M. J.

PY - 1986/3

Y1 - 1986/3

N2 - A study has been carried out investigating four different marketed oral preparations of glibenclamide, correlating the effectiveness of the drug in these preparations in lowering plasma glucose concentrations with (i) the in vitro dissolution of the drug, measured by the British Pharmacopoeal and Desaga methods, and (ii) the in vivo bioavailability, assessed in 12 healthy human volunteers. The two dissolution methods yielded different rank orders of ease of dissolution of the drug from the various preparations; the findings of neither dissolution method correlated adequately with the results of the in vivo bioavailability studies, which correctly predicted the abilities of the preparations to reduce plasma glucose concentrations. Relative to an oral glibenclamide solution the bioavailabilities of the drug from three tablet preparations were 0.69, 0.49 and 0.24. The mean elimination half-life of the drug was 1.5 h and assuming complete bioavailability of the drug from oral solution the mean systemic clearance was 0.095 l kg-1h-1, and the mean apparent volume of distribution was 0.20 l kg-1. It is concluded that it may be unsafe to use in vitro dissolution data as a basis for assessing the bioequivalences of different glibenclamide preparations intended for oral use.

AB - A study has been carried out investigating four different marketed oral preparations of glibenclamide, correlating the effectiveness of the drug in these preparations in lowering plasma glucose concentrations with (i) the in vitro dissolution of the drug, measured by the British Pharmacopoeal and Desaga methods, and (ii) the in vivo bioavailability, assessed in 12 healthy human volunteers. The two dissolution methods yielded different rank orders of ease of dissolution of the drug from the various preparations; the findings of neither dissolution method correlated adequately with the results of the in vivo bioavailability studies, which correctly predicted the abilities of the preparations to reduce plasma glucose concentrations. Relative to an oral glibenclamide solution the bioavailabilities of the drug from three tablet preparations were 0.69, 0.49 and 0.24. The mean elimination half-life of the drug was 1.5 h and assuming complete bioavailability of the drug from oral solution the mean systemic clearance was 0.095 l kg-1h-1, and the mean apparent volume of distribution was 0.20 l kg-1. It is concluded that it may be unsafe to use in vitro dissolution data as a basis for assessing the bioequivalences of different glibenclamide preparations intended for oral use.

KW - bioavailability

KW - dissolution

KW - glibenclamide

KW - healthy volunteers

KW - hypoglycaemia

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0022909293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022909293&partnerID=8YFLogxK

U2 - 10.1007/BF00606655

DO - 10.1007/BF00606655

M3 - Article

VL - 31

SP - 177

EP - 182

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 2

ER -